Tacrolimus nanocrystal-loaded glycyrrhizic acid hydrogel for the treatment of corneal alkali burn
Journal of Controlled Release · 2026
DOI: 10.1016/j.jconrel.2026.115149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2026. Verfasst von Wen Ran und 9 weiteren Autor:innen. Beteiligte Einrichtung: Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China. Hauptthemen laut MEDLINE: Glycyrrhizic Acid, Burns, Chemical, Nanoparticles, Eye Burns. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Corneal alkali burn (CAB) is a severe ophthalmic emergency that causes extensive damage to the ocular surface and anterior segment. Its primary threat lies in visual impairment resulting from poor recovery, which is largely driven by persistent chronic inflammation. Although corticosteroids are commonly used in clinical practice to control inflammation, their long-term use is limited by risks of corneal melting, glaucoma, and delayed epithelial healing. In this study, a glycyrrhizic acid-based supramolecular hydrogel system (GA gel) loaded with tacrolimus nanocrystals (Tac NCs) was developed to provide an anti-inflammatory effect for chronic inflammation intervention. Formulating tacrolimus into nanocrystals not only improved its solubility in tears but also enhanced its binding to mucin, thereby achieving sustained local exposure. Moreover, the GA gel served as a carrier that prolonged precorneal retention, while also exhibiting anti-inflammatory and antioxidant activities, thereby complementing the Tac NCs. In a rat model of CAB, the Tac NCs-loaded GA gel (Tac@ GA gel) significantly promoted corneal epithelial repair, restored stromal transparency, and inhibited neovascularization. In conclusion, the Tac@GA gel represented a promising drug delivery platform for the comprehensive management of chronic ocular surface inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, PR China.
- School of Pharmacy, Shenyang Pharmaceutical University, Benxi, Liaoning 117004, PR China.
- Department of Dermatology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
- Department of Pharmaceutics, School of Pharmacy, China Medical University, Liaoning 110122, China.
- Department of Pharmaceutics, School of Pharmacy, China Medical University, Liaoning 110122, China. Electronic address: yanzhao@cmu.edu.cn.
- Department of Dermatology, Shengjing Hospital of China Medical University, Shenyang 110004, China. Electronic address: crab0@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ran, W., Yang, Y., Li, J., Huang, R., Qin, Y., Zhou, J., Ding, C., Zhao, Y., Yang, F., & Wang, Y. (2026). Tacrolimus nanocrystal-loaded glycyrrhizic acid hydrogel for the treatment of corneal alkali burn. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2026.115149
Vancouver
Ran W, Yang Y, Li J, Huang R, Qin Y, Zhou J, et al. Tacrolimus nanocrystal-loaded glycyrrhizic acid hydrogel for the treatment of corneal alkali burn. Journal of Controlled Release. 2026. doi:10.1016/j.jconrel.2026.115149
BibTeX
@article{Ran2026,
author = {Ran, Wen and Yang, Yang and Li, Jiawei and Huang, Ruiping and Qin, Yang and Zhou, Junjie and Ding, Chengke and Zhao, Yan and Yang, Fan and Wang, Yongjun},
title = {Tacrolimus nanocrystal-loaded glycyrrhizic acid hydrogel for the treatment of corneal alkali burn},
journal = {Journal of Controlled Release},
year = {2026},
doi = {10.1016/j.jconrel.2026.115149}
}
EUVIMED